These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29271413)

  • 1. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
    Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
    Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
    Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
    Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
    Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
    Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
    Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
    Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
    Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
    Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
    Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
    Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
    Front Immunol; 2022; 13():954910. PubMed ID: 35967344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
    Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
    Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
    Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
    BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
    Grabenstetter A; Jungbluth AA; Frosina D; Hoda R; Dos Anjos CH; Patil S; Sevilimedu V; Weigelt B; Reis-Filho JS; Zhang H; Traina T; Robson ME; Brogi E; Wen HY
    Am J Surg Pathol; 2021 Sep; 45(9):1274-1281. PubMed ID: 34115674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
    Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.